Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

23,630 total articles

Colorado PPE Opens New Colorado Facility to Deliver Firefighter PPE Care Above and Beyond Standard Compliance

Colorado PPE Opens New Colorado Facility to Deliver Firefighter PPE Care Above and Beyond Standard Compliance

Lakeland Industries, Inc., through its independent service provider Colorado PPE, has opened a new facility in Centennial, Colorado. The facility offers comprehensive services for firefighter personal protective equipment (PPE) including cleaning, inspection, repair, rental, and NFPA 1850 training, aiming to exceed industry standards to better prot…

Idaho Copper Receives U.S. Forest Service Approval to Commence Drilling at Flagship CuMo Copper-Molybdenum Project

Idaho Copper Receives U.S. Forest Service Approval to Commence Drilling at Flagship CuMo Copper-Molybdenum Project

Idaho Copper Corporation received the U.S. Forest Service's approval for its Exploration Plan of Operations and 2026 annual operating plan, enabling the company to commence drilling activities at its CuMo copper-molybdenum-silver project in Boise County, Idaho. This clears the regulatory path after a decade of work and signals a transition toward a…

Fiserv Expands Clover Footprint in Canadian Sports and Entertainment

Fiserv Expands Clover Footprint in Canadian Sports and Entertainment

Fiserv announces that its Clover commerce platform has been selected by the Winnipeg Blue Bombers to manage commerce operations at their stadium, marking a significant expansion of Fiserv's presence in Canada’s sports, entertainment, and hospitality sectors. Clover supports multiple Canadian Football League venues and offers integrated payment proc…

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

SAB Biotherapeutics, a clinical-stage biopharmaceutical company listed on Nasdaq (SABS), announced multiple presentations featuring their lead candidate SAB-142 at the 62nd European Association for the Study of Diabetes meeting. SAB-142 is a novel, human anti-thymocyte immunoglobulin therapy showing potential to modify disease progression in Stage …

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

Propanc Biopharma, Inc. highlights new preclinical data demonstrating that its lead candidate PRP achieves over 90% tumor growth inhibition and more than 2.5-fold survival benefit in pancreatic ductal adenocarcinoma (PDAC) models. PRP works by promoting cancer cell differentiation and reversing mechanisms like EMT and cancer stem cell presence, whi…

Grayscale Investments Introduces Grayscale AI Compute ETF (Ticker: GCPU), Targeting the Infrastructure Powering AI's Growth

Grayscale Investments Introduces Grayscale AI Compute ETF (Ticker: GCPU), Targeting the Infrastructure Powering AI's Growth

Grayscale Investments has introduced the Grayscale AI Compute ETF (GCPU), targeting companies involved in the physical infrastructure critical to AI's rapid expansion. The new fund tracks the Indxx High Performance Computing Index and provides exposure to firms building and transitioning operations toward AI workloads, reflecting a projected $1 tri…

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals announced the FDA granted Fast Track Designation for QRX003 to treat Peeling Skin Syndrome (PSS), a rare genetic skin disease with no approved therapies. This is the first Fast Track granted for PSS treatment and the second for QRX003, which also has Fast Track status for Netherton Syndrome. Following FDA clearance of the firs…

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

Compass Therapeutics announced that the FDA recommended conducting an additional trial to prove a survival benefit for its drug tovecimig in advanced biliary tract cancer prior to Biologics License Application submission. Compass disagrees with the FDA's recommendation, citing positive Phase 2/3 trial results showing significant improvements in obj…

Zeo Energy Enters Cooperation Agreement with Ewyze to Develop Integrated Off-Grid Power and Data-Center Infrastructure

Zeo Energy Enters Cooperation Agreement with Ewyze to Develop Integrated Off-Grid Power and Data-Center Infrastructure

Zeo Energy Corp. has entered a cooperation agreement with Ewyze Corp. to jointly develop and commercialize integrated off-grid power microgrids combined with data-center infrastructure in the U.S. and selected international markets. This partnership addresses the growing demand for AI-capable, reliable, and scalable power solutions amid challenges …

Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

Aprea Therapeutics announced that updated interim results from its Phase 1 trial of the WEE1 inhibitor APR-1051 in advanced solid tumors will be presented orally at the 38th EORTC-NCI-AACR Symposium. The data presentation highlights progress in their targeted cancer therapy pipeline, potentially impacting multiple tumor types including ovarian, col…

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen announced positive preliminary data from the open-label extension portion of its PALISADE-4 Phase 3 study evaluating fasedienol for acute treatment of social anxiety disorder. The nasal spray was well-tolerated with no new safety issues during up to 12 months of as-needed use. Exploratory efficacy assessments showed clinically relevant imp…

SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner

SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner

Scienture Holdings, Inc. announced an exclusive sales, marketing, and distribution agreement to distribute its FDA-approved REZENOPY™ naloxone hydrochloride nasal spray through a partner's network of approximately 2,000 Opioid Treatment Program (OTP) clinics and addiction treatment centers across the United States. The agreement complements Scientu…

PREMIUM WINE AND CAVIAR COMPANY TOP WEALTH GROUP HOLDING LIMITED RELOCATES GLOBAL HEADQUARTERS FROM HONG KONG, CHINA TO LILLE, FRANCE, SIGNALING STRATEGIC PIVOT TO GLOBAL MARKETS

PREMIUM WINE AND CAVIAR COMPANY TOP WEALTH GROUP HOLDING LIMITED RELOCATES GLOBAL HEADQUARTERS FROM HONG KONG, CHINA TO LILLE, FRANCE, SIGNALING STRATEGIC PIVOT TO GLOBAL MARKETS

Top Wealth Group Holding Limited, a NASDAQ-listed premium caviar and wine supplier, announced the relocation of its global headquarters from Hong Kong to Lille, France. This strategic move supports the company's shift from a regional Asian focus to a wider global luxury food and beverage market presence. The relocation aims to enhance distribution …

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

IMUNON's DNA-based immunotherapy candidate IMNN-001 demonstrated a favorable safety profile with no serious immune-related adverse events in an ongoing Phase 2 minimal residual disease (MRD) study for advanced ovarian cancer. The Independent Data Monitoring Committee recommended continuation without modifications, validating the drug's tolerability…

Roundtable Files 8-K: Projects $90-$100 Million in 2027 Revenue and Annualized Adjusted EBITDA-Positive Operations

Roundtable Files 8-K: Projects $90-$100 Million in 2027 Revenue and Annualized Adjusted EBITDA-Positive Operations

Roundtable (NASDAQ: RTB), an AI/DeFi-powered Enterprise Media Operating System, announced in a Form 8-K filing its 2027 forecast projecting $102 million in revenue and achieving annualized Adjusted EBITDA-positive operations. The forecast incorporates the Paradium.AI partnership, expected to drive significant operating leverage due to fixed costs a…

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology

PDS Biotechnology Corporation announced the publication of Phase 2 clinical trial results in JAMA Oncology demonstrating that PDS0101, an HPV16-targeted immunotherapy combined with pembrolizumab, achieved a median overall survival of 39.3 months in immune checkpoint inhibitor-naïve patients with recurrent/metastatic HPV16-positive head and neck can…

Comscore's Latest AI Intelligence Report Shows Competition Intensifying as Claude and Gemini Gain Ground on ChatGPT

Comscore's Latest AI Intelligence Report Shows Competition Intensifying as Claude and Gemini Gain Ground on ChatGPT

Comscore's latest report highlights a diversification in AI assistant usage among consumers. While ChatGPT remains the leader, its market share has decreased from 70% to 50% between January and June 2026, as competitors Claude and Google's Gemini increase their shares significantly. AI assistant adoption on mobile devices is accelerating, and AI is…

TTEC Launches New Automotive Customer Experience Program in Cairo

TTEC Launches New Automotive Customer Experience Program in Cairo

TTEC Holdings, Inc. has launched a new customer experience operation in Cairo to support Volkswagen Group UK's customer care across digital and voice channels. This expansion leverages TTEC's multilingual workforce, AI-enabled CX technologies, and automotive expertise, enhancing service quality as part of a seven-year strategic collaboration with V…

newcleo Begins Trading on Nasdaq Under Symbol "NWCL"

newcleo Begins Trading on Nasdaq Under Symbol "NWCL"

newcleo plc, a pioneer in advanced modular reactor technology and nuclear fuel manufacturing, has started trading on the Nasdaq Global Select Market under the ticker symbol NWCL. The listing supports the company’s growth plans, including completing a demonstrator reactor in Italy, advancing regulatory approvals in the U.S. and Europe, and expanding…